Stay updated on Clinical Trial: MK-3475 Combo in Renal Cell Carcinoma

Sign up to get notified when there's something new on the Clinical Trial: MK-3475 Combo in Renal Cell Carcinoma page.
Latest website image capture
Clouds background image

Latest updates to the Clinical Trial: MK-3475 Combo in Renal Cell Carcinoma page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the dose escalation study evaluating MK-3475 in combination with bevacizumab for subjects with metastatic clear cell renal carcinoma after failure of systemic therapy.
    Difference
    0.1%
    Check dated 2024-06-06T14:44:49.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    49%
    Check dated 2024-05-22T21:27:30.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T21:54:56.000Z thumbnail image

Stay in the know with updates to Clinical Trial: MK-3475 Combo in Renal Cell Carcinoma

Enter your email address, and we'll notify you when there's something new on the Clinical Trial: MK-3475 Combo in Renal Cell Carcinoma page.